Telix Pharmaceuticals Limited
TLXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Telix Pharmaceuticals Limited (TLX) is listed under Biotechnology. The company carries a $4.06B market cap, placing it firmly in the mid-cap category. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Market Cap
$4.06B
Beta
0.60
P/E (TTM)
119.40
P/E (Fwd)
82.11
EPS (TTM)
$0.10
EPS (Fwd)
$0.15
ROE
7.4%
ROA
2.7%
Cash
$251.9M
Total Debt
$579.9M
Free CF
-$62.6M
52W Change
29.7%
Annual Financials
Cash vs Debt
Where TLX stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, TLX finished 16.63% above its 150-day moving average ($9.68) and 20.11% above its 200-day moving average ($9.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TLX overbought or oversold?
At the August 31, 2026 close, TLX's RSI(14) was 44.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $251.9M in cash, though total debt stands at $579.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$62.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 7.4% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $108.9M (2022) to $803.8M (2025), reflecting a 638% increase over the period.
With a beta below 0.7, Telix Pharmaceuticals Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. At over 50x earnings, TLX carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Telix Pharmaceuticals Limited and its sector.